

Trading statement Q1 2024

Novonesis realized 4% organic sales growth in line with expectations and maintains 2024 outlook.

Ester Baiget, President & CEO: *“I am pleased with the first quarter organic sales growth of 4% with growth in both Food & Health and Planetary Health. We are off to a good start in line with expectations and very well on track to deliver 5-7% organic sales growth for the full year with an adjusted EBITDA margin of around 35%. It’s highly comforting to see our new organization’s focus on both short and long-term deliverables and developments.”*

Pro forma sales performance¹ (organic sales growth calculation capped for hyperinflation countries)

Against a strong comparable Novonesis realized 4% pro forma organic sales growth in Q1 2024. Volumes increased by around 2% and pricing also contributed around 2%. Pro forma sales in EUR amounted to 965.5 million, an increase of 1% (organic +4%, currency -2%, M&A -1%). Emerging markets grew 14% organically, while developed markets declined 1%.

- Food & Health Biosolutions** realized pro forma organic sales growth of 3% for Q1 2024. Pro forma sales in EUR were 424.8 million, a decrease of 2% (organic +3%, currency -2%, M&A -3%). The divestment relates to the lactase enzyme business. Food & Beverages grew 6% organically, while Human Health declined 5%, in line with expectations. Food & Beverages was driven by strong growth in Dairy and solid growth in Baking. As expected, Human Health had a soft start to the year due to a strong comparable and order timing in both HMO and Dietary supplements.
- Planetary Health Biosolutions** realized pro forma organic sales growth of 5% for Q1 2024. Pro forma sales in EUR were 540.7 million, an increase of 3% (organic +5%, currency -2%). Household Care grew 15% organically with growth across all regions. Agriculture, Energy & Tech was flat with double-digit growth in Energy and a demanding comparable in Agriculture.

Reported (IFRS) sales performance (Chr. Hansen included as of January 29, 2024)

Novonesis reported 4% organic sales growth according to IFRS reporting. Reported sales in EUR were 853.5 million (Q1 2023: EUR 621.1 million). Please see Appendix 2 for further details.

2024 outlook¹

Novonesis maintains its sales and profitability outlook for 2024 with pro forma organic sales growth of 5-7% and a pro forma adjusted EBITDA margin at ~35%. Food & Health Biosolutions is indicated to grow organically in the mid-to-high single digits and Planetary Health Biosolutions is indicated to grow mid-single digit. Growth in Food & Beverages is expected to be driven by broad performance across subareas. Growth in Human Health is expected to be driven by sales of Advanced Protein Solutions to the anchor customer as well as by Dietary Supplements. Household Care is expected to be driven by increased penetration across markets. Agriculture, Energy & Tech is expected to be driven by growth across all subareas led by Energy.


	Pro forma Q1 2024	Pro forma Q1 2023	Reported (IFRS) Q1 2024	Reported (IFRS) Q1 2023
Organic sales growth, %				
Total sales	4%	6%	4%	5%
Food & Health Biosolutions	3%	3%	3%	-8%
Food & Beverages	6%	2%	3%	-7%
Human Health	-5%	5%	2%	-17%
Planetary Health Biosolutions	5%	9%	5%	14%
Agriculture, Energy & Tech	0%	13%	0%	2%
Household Care	15%	2%	15%	34%

Conference call
 May 3, 2024
 9.00 CEST
 Please pre-register for the call [here](#).
[Webcast](#)

¹ The outlook 2024 is based on 12 months pro forma numbers for the consolidated business. The 2024 IFRS reported numbers are expected to be similar, i.e. same outlook. Refer to Company Announcement no. 11 – March 21, 2024 for further details.

Sales by area

Distribution of pro forma sales by area, Q1 2024



Total pro forma sales Q1 y/y
Organic: 4%
EUR: 1%

FOOD & HEALTH BIOSOLUTIONS

Food & Beverages

Food & Beverages grew 6% organically in Q1 2024, and pro forma sales in EUR were flat. The divestment of part of the lactase enzyme business had a negative 4 percentage point impact in the quarter since this business is no longer shown as revenue in 2024. The organic performance was driven by strong growth in Dairy, solid development in Baking and a softer performance in Beverages. The destocking impacting last year's performance has levelled off. Growth in Dairy was supported by both fresh dairy and cheese, driven by upselling and strong customer adoption of new innovation. In Dairy, China was a positive contributor to organic growth in the quarter. Baking delivered a solid start to the year and Beverages were softer mainly due to timing.

Food & Beverages pro forma Q1 y/y
Organic: 6%
EUR: 0%

Human Health

Human Health declined 5% in Q1 2024, and pro forma sales in EUR were down 6%. Human Health had a soft start to the year in line with expectations due to a strong comparable and order timing in HMO and Dietary supplements. Performance of Dietary supplements in Asia Pacific was strong, driven by good growth in Infant & Children and Women probiotics. The first sales to the Advanced Protein Solutions anchor customer from the new facility in Blair were realized, with a successful on-schedule start-up of the plant.

Human Health pro forma Q1 y/y
Organic: -5%
EUR: -6%

PLANETARY HEALTH BIOSOLUTIONS

Household Care

Household Care grew 15% organically in Q1 2024, and pro forma sales in EUR were up 14%. All regions contributed to the double-digit growth, which was driven by increased penetration and innovation including a positive effect from timing. The industry volume growth across markets was also supportive.

Household Care pro forma Q1 y/y
Organic: 15%
EUR: 14%


Agriculture, Energy & Tech

Agriculture, Energy & Tech was flat in Q1 2024, and pro forma sales in EUR were down 2%. The comparable was demanding as Animal Nutrition had a very strong Q1 performance in 2023 due to the timing of orders. Due to continued destocking, the performance of Plant was also softer. Bioenergy grew double-digit and was supported by favorable market conditions and increased penetration, especially in North America. Latin America also performed well, driven by capacity expansion of ethanol production, including volumes for second-generation ethanol. Tech grew slightly driven by both grain and textile.

Agriculture, Energy & Tech pro forma Q1 y/y
Organic: 0%
EUR: -2%

Sales by region

Distribution of pro forma sales by region, Q1 2024



Organic sales in developed markets declined 1% in the first quarter of 2024, driven by a decline in Human Health and soft performance in Agriculture, Energy & Tech and partly offset by growth in Household Care and Food & Beverages.

Emerging markets reported organic sales growth of 14% in Q1 2024 driven by double-digit growth across all sales areas.

Europe, the Middle East & Africa

Organic sales for Europe, the Middle East & Africa grew 2% in Q1 2024 driven by Household Care and Food & Beverages, while Human Health and Agriculture, Energy & Tech declined.

North America

Q1 2024 organic sales in North America declined 1%. The performance was driven by strong growth in Household Care as well as in Energy as part of Agriculture, Energy & Tech. This was offset by a year-on-year comparable and continued destocking in Agriculture as well as timing and a demanding comparable in Human Health.

Asia Pacific

Asia Pacific reported 13% organic sales growth in Q1 2024 driven by all sales areas with Household Care, Human Health and Agriculture, Energy & Tech as the strongest contributors followed by solid growth also in Food & Beverages.

Latin America

Organic sales for Latin America grew 10% in Q1 2024 driven by growth across all sales areas.

Developed markets pro forma Q1 y/y

Organic: -1%
EUR: -3%

Emerging markets pro forma Q1 y/y

Organic: 14%
EUR: 9%

Europe, the Middle East & Africa pro forma Q1 y/y

Organic: 2%
EUR: -1%

North America pro forma Q1 y/y

Organic: -1%
EUR: -2%

Asia Pacific pro forma Q1 y/y

Organic: 13%
EUR: 8%

Latin America pro forma Q1 y/y

Organic: 10%
EUR: 6%

Contacts

Investor Relations

Tobias Bjorklund	+45 3077 8682	tobb@novonesis.com
Anders Enevoldsen	+45 5350 1453	adev@novonesis.com
Disa Tuominen	+45 6038 5826	ditu@novonesis.com

Media Relations

Lina Danstrup	+45 3077 0552	lind@novonesis.com
---------------	---------------	--------------------

Financial calendar 2024

June 18, 2024: Capital Markets Day in London
August 28, 2024: H1 announcement 2024
November 7, 2024: Trading statement 9M 2024

Appendices

Appendix 1 Pro forma: Distribution of sales	6
1.1 Sales by area	6
1.2 Sales by region	6
Appendix 2 Reported (IFRS): Distribution of sales*	7
2.1 Sales by area	7
2.2 Sales by region	7

Appendix 1 Pro forma: Distribution of sales

1.1 Sales by area

EUR million	Pro forma					
	2024 Q1	2023 Q1	% change	% currency impact	% M&A impact	% organic growth
Food & Health Biosolutions						
Food & Beverages	317.4	318.6	0	(2)	(4)	6
Human Health	107.4	114.2	(6)	(1)	0	(5)
	424.8	432.8	(2)	(2)	(3)	3
Planetary Health Biosolutions						
Agriculture, Energy & Tech	348.8	354.8	(2)	(2)	0	0
Household Care	191.9	168.9	14	(1)	0	15
	540.7	523.7	3	(2)	0	5
Net sales	965.5	956.5	1	(2)	(1)	4

EUR million	Pro forma					
	2024 Q1	2023 Q4	2023 Q3	2023 Q2	2023 Q1	% change Q1/Q1
Food & Health Biosolutions						
Food & Beverages	317.4	320.4	326.3	315.8	318.6	0
Human Health	107.4	104.3	110.1	111.1	114.2	(6)
	424.8	424.7	436.4	426.9	432.8	(2)
Planetary Health Biosolutions						
Agriculture, Energy & Tech	348.8	340.6	328.7	313.7	354.8	(2)
Household Care	191.9	177.3	177.9	161.1	168.9	14
	540.7	517.9	506.6	474.8	523.7	3
Net sales	965.5	942.6	943.0	901.7	956.5	1

Note: The above figures are calculated on a pro forma basis including three months of both legacy Novozymes and Chr. Hansen sales.

1.2 Sales by region

EUR million	Pro forma					
	2024 Q1	2023 Q1	% change	% currency impact	% M&A impact	% organic growth
Europe, Middle East & Africa	345.4	350.1	(1)	(1)	(2)	2
North America	311.1	318.5	(2)	0	(1)	(1)
Asia Pacific	189.2	175.4	8	(4)	(1)	13
Latin America	119.8	112.5	6	(2)	(2)	10
Net sales	965.5	956.5	1	(2)	(1)	4
Developed markets	620.9	641.3	(3)	(1)	(1)	(1)
Emerging markets	344.6	315.2	9	(4)	(1)	14
Net sales	965.5	956.5	1	(2)	(1)	4

EUR million	Pro forma					
	2024 Q1	2023 Q4	2023 Q3	2023 Q2	2023 Q1	% change Q1/Q1
Europe, Middle East & Africa	345.4	328.7	340.6	327.2	350.1	(1)
North America	311.1	311.0	311.5	299.1	318.5	(2)
Asia Pacific	189.2	182.2	168.9	164.7	175.4	8
Latin America	119.8	120.7	122.0	110.7	112.5	6
Net sales	965.5	942.6	943.0	901.7	956.5	1
Developed markets	620.9	606.2	610.1	594.3	641.3	(3)
Emerging markets	344.6	336.4	332.9	307.4	315.2	9
Net sales	965.5	942.6	943.0	901.7	956.5	1

Note: The above figures are calculated on a pro forma basis including three months of both legacy Novozymes and Chr. Hansen sales.

Appendix 2 Reported (IFRS): Distribution of sales*

2.1 Sales by area

EUR million	2024 Q1	2023 Q1	% change	% currency impact	% M&A impact	% organic growth
Food & Health Biosolutions						
Food & Beverages	245.4	117.5	109	0	106	3
Human Health	76.6	19.0	303	3	298	2
	322.0	136.5	136	0	133	3
Planetary Health Biosolutions						
Agriculture, Energy & Tech	339.6	315.7	8	(1)	9	0
Household Care	191.9	168.9	14	(1)	0	15
	531.5	484.6	10	(1)	6	5
Net sales	853.5	621.1	37	(1)	34	4

EUR million	2024 Q1	2023 Q4	2023 Q3	2023 Q2	2023 Q1	% change Q1/Q1
Food & Health Biosolutions						
Food & Beverages	245.4	108.9	111.6	106.2	117.5	109
Human Health	76.6	23.2	22.2	21.5	19.0	303
	322.0	132.1	133.8	127.7	136.5	136
Planetary Health Biosolutions						
Agriculture, Energy & Tech	339.6	307.7	286.2	277.2	315.7	8
Household Care	191.9	177.3	178.0	161.1	168.9	14
	531.5	485.0	464.2	438.3	484.6	10
Net sales	853.5	617.1	598.0	566.0	621.1	37

2.2 Sales by region

EUR million	2024 Q1	2023 Q1	% change	% currency impact	% M&A impact	% organic growth
Europe, Middle East & Africa	303.8	223.7	36	0	35	1
North America	279.6	207.1	35	(1)	34	2
Asia Pacific	164.1	115.5	42	(2)	32	12
Latin America	106.0	74.8	42	2	30	10
Net sales	853.5	621.1	37	(1)	34	4
Developed markets	549.4	408.6	34	(2)	35	1
Emerging markets	304.1	212.5	43	0	31	12
Net sales	853.5	621.1	37	(1)	34	4

EUR million	2024 Q1	2023 Q4	2023 Q3	2023 Q2	2023 Q1	% change Q1/Q1
Europe, Middle East & Africa	303.8	205.9	211.1	196.3	223.7	36
North America	279.6	218.8	196.6	190.9	207.1	35
Asia Pacific	164.1	114.1	108.0	106.1	115.5	42
Latin America	106.0	78.3	82.3	72.7	74.8	42
Net sales	853.5	617.1	598.0	566.0	621.1	37
Developed markets	549.4	398.5	378.2	364.8	408.6	34
Emerging markets	304.1	218.6	219.8	201.2	212.5	43
Net sales	853.5	617.1	598.0	566.0	621.1	37

Note: *The above figures are calculated on an IFRS basis including three months of legacy Novozymes sales and two months of legacy Chr. Hansen sales as the merger was finalized on January 29, 2024.

Pro forma financial measures

The pro forma financials for Novonesis are reported as a combination of the consolidated financials provided by Novozymes A/S and Chr. Hansen Holding A/S as if the combination of the Novozymes A/S and Chr. Hansen Holding A/S became effective from 1 January 2023 (instead of January 29, 2024). The pro forma financials are unaudited and illustrative. Refer to Company Announcement no. 11 – March 21, 2024, for further details on the pro forma financials for 2023.

Non-IFRS financial measures and definitions**Organic sales growth**

Sales growth from existing business excluding divestments in constant currencies and for IAS 29 defined hyperinflation countries with a cap of 26% on inflation driven sales growth. For acquisitions, pro forma sales for the comparative ownership period are included in the calculation. Constant currency values are calculated by translating both the current and the prior period local currency amounts using the same exchange rates into Euro. The pro forma organic sales growth has been prepared as if the merger had been completed on January 1, 2024 instead of January 29, 2024.

Information regarding forward-looking statements

This announcement includes forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the control of the combined group and all of which are based on the combined group's current beliefs and expectations about future events. Forward-looking statements are sometimes identified by the use of forward-looking terminology such as "aim", "annualized", "anticipate", "assess", "assume", "believe", "continue", "could", "estimate", "expect", "goal", "hope", "intend", "may", "objective", "plan", "position", "potential", "predict", "project", "risk", "seek", "should", "target", "will" or "would" or the highlights or the negatives thereof, other variations thereon or comparable terminology. The forward-looking statements include all matters that are not historical facts. They appear in a number of places throughout this announcement and other documents regarding the combination and include statements that reflect the combined group's intentions, beliefs, or current expectations and projections about their respective future results of operations, financial condition, liquidity, performance, prospects, anticipated growth, targets, strategies, and opportunities, as well as the markets in which they respectively operate. The forward-looking statements and other statements contained in this announcement regarding matters that are not historical facts involve predictions. No assurance can be given that such future results will be achieved; actual events or results may differ materially as a result of risks and uncertainties facing the combined group. Such risks and uncertainties could cause actual results to vary materially from the future results indicated, expressed, or implied in such forward-looking statements. Forward-looking statements in this announcement speak only as of the date of this announcement. The information contained in this announcement is subject to change without notice, and, except as required by applicable laws and regulations, the combined group expressly disclaims any obligation or undertaking to update or revise the forward-looking statements contained in this announcement to reflect any change in its expectations or any change in events, conditions, or circumstances on which such statements are based, and nor does it intend to. Investors should not place undue reliance on forward-looking statements, which speak only as of the date of this announcement. As a result of these risks, uncertainties, and assumptions, you should not place undue reliance on these forward-looking statements as a prediction of actual future events or otherwise.

Novonesis is a global company leading the era of biosolutions.

By leveraging the power of microbiology with science, we transform the way the world produces, consumes and lives. In more than 30 industries, our biosolutions are already creating value for thousands of customers and benefiting the planet. Our 10,000 people worldwide work closely with our partners and customers to transform business with biology.

**Novozymes A/S, part of
Novonesis Group**
Krogshøjvej 36
2880 Bagsvaerd
Denmark